Clinical Trial Update: Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating twice-daily lansoprazole (Prevacid) for treatment of laryngopharyngeal reflux has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngopharyngeal Reflux

Drugs mentioned

• PREVACID (LANSOPRAZOLE)

Snippet

Sponsor: University of California, Davis | Conditions: Laryngopharyngeal Reflux | Phase 1 | Status: COMPLETED